Personalized Nutrition for...



Many patients with digestive health issues are unable to efficiently absorb and process health sustaining essential nutrients the body needs to maintain cell growth, cell maintenance, weight and overall wellness.  Existing foods and nutrients are structured for healthy digestive systems, not compromised systems.

Our medical food products are tuned to address this problem in patients with various health conditions including:



Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic fibrosis (CF) is a genetically inherited disorder affecting one in every 4000 newborns. It occurs due to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.  The loss of functional CFTR protein impacts breathing and lung function, digestion of lipids by the pancreas, and the immune system’s ability to fight infection. CFTR regulates the production of sweat, digestive fluids and mucus. Without functional CFTR, thick mucus builds up in the lungs and gastrointestinal organs, making breathing difficult and leading to bacterial and fungal infections, and malnutrition due to the increased energy requirement of this disease combined with partial exocrine pancreatic insufficiency (EPI). 

Nutritional supplementation for CF patients is critical to their long term survival but becomes burdensome due to the need for pancreatic enzyme replacement therapy (PERT) with every meal to ensure proper digestion and maintain caloric requirements of the body for a healthy weight.


GlycosBio’s highly bioavailable formula is the first product of its kind that addresses the needs of CF patients and allows for a ready source of total essential nutrition that the body can assimilate without digestion.


GlycosBio is evaluating its medical food products in a randomized, double-blind, cross-over trial assessing a nutritional therapeutic delivery option for cystic fibrosis patients that does not require separate pancreatic enzymatic replacement therapy. The safety and tolerability of GlycosBio’s highly bioavailable nutritional shakes compared to standard nutritional shakes used concomitantly with pancreatic enzymatic replacement therapy (PERT) will be assessed.


Chronic Obstructive Pulmonary Disease (COPD)

COPD is one of the leading causes of death worldwide and is a growing concern as the elderly population rises. Globally, more than 250 million people are living with COPD and 3.2 million deaths were attributed to COPD in 2015 (1).  COPD is characterized by progressive airflow obstruction and inflammation in the lungs leading to difficulty breathing. Difficulty breathing leads to difficulty eating, or patients not wanting to eat at all, despite the high resting energy requirements needed to breath (2).  Pulmonary cachexia is estimated to occur in up to 40% of COPD patients, characterized by muscle wasting, weight loss, reduced exercise capacity and systemic inflammation (3-5). The presence of cachexia in COPD accelerates decline and is a determinant of mortality. Like CF patients, COPD patients have an increased resting energy expenditure (REE) and are in a state of hypermetabolism, requiring more calories to maintain weight. Maintaining fat-free mass is necessary to prevent the effects of cachexia. Nutritional support to increase caloric intake, build muscle, and reduce inflammation are critical needs to offset accelerating disease.


The GlycosBio nutritional platform offers these patients a new way of supporting muscle maintenance and immuno-nutrition with a quickly and readily absorbable formula that the body can assimilate without effort. 



  3. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. Karin JC Sanders, et al., J Cachexia Sarcopenia Muscle. (2016) Mar; 7(1): 5–22.

  4. Nutrition in chronic obstructive pulmonary disease: A review. Gautam Rawal and Sankalp Yadav, J Transl Int Med. (2015) Oct-Dec; 3(4): 151–154.

  5. Nutritional aspects of chronic obstructive pulmonary disease. King DA, et al., Proc Am Thorac Soc. (2008) May 1;5(4):519-23.


Cancer Cachexia and Malnutrition

Cancer is a group of diseases that will impact 40% of the population at some point in their lives (1). Currently there are over 14 million people with cancer and in the US, almost 1.7 million people are diagnosed with cancer every year (2-3). Cachexia, muscle wasting associated with fat-free weight loss caused by systemic inflammation, energy inefficiency, and anorexia, impacts between 50-80% of all cancer patients depending on the type of cancer, and leads to death (4-6). Nutritional support in cancer treatment and post-recovery is crucial to helping patients manage treatment side effects, improve quality of life, and to thrive in remission. Recent studies demonstrated worse remission rates in malnourished leukemia patients, and in non-metastatic breast cancer, undernutrition resulted in higher mortality rates (7,8).  To offset added complications during cancer treatment and improve survival outcome, a fast-acting complete nutritional source for essentials amino acids, vitamins, and fatty acids that does not induce gastrointestinal upset can make the difference in keeping cancer patients fortified and prepared to fight.

Nutrition based on optimized formulas offers everything necessary for patients who have difficulty eating but require a source of calories, protein, vitamins and fats that is easily absorbed and well tolerated. 





  4. Cancer cachexia: one step ahead. Meriggi F, Rev Recent Clin Trials (2015) 10, 246–250. 

  5. Cancer cachexia: understanding the molecular basis. Argilés JM, et al., Nat Rev Cancer. (2014) Nov;14(11):754-62

  6. Malnutrition and cachexia among cancer out-patients in Nairobi. Kenya LU, et al., Kaduka Journal of Nutritional Science (2017) vol. 6, e63, page 1 of 10

  7. Assessment of the nutritional status of adult patients with acute myeloid leukemia during induction chemotherapy. Deluche E, et al., Nutrition 41 (2017) 120–125

  8. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. Caan BJ, et al., JAMA Oncol. (2018) April 5

Elderly Sarcopenia

The definition of “elderly” by the World Health Organization (WHO) is a person 65+ years of age (1). Advancements in medical care for all types of diseases has led to the expected number of elderly in the US to reach 80 million by 2050, comprising 20% of the US population (2). Sarcopenia is the loss of muscle mass and strength due to aging and is responsible for frailty, increased dependence for daily living and mortality. Options to increase muscle strength and nutritional balance to geriatric individuals is paramount to maintaining independence and quality of life while reducing the burden on the healthcare system.

Research supports nutritional intervention as an approach for assisting the health of geriatric patients. A calorie rich nutritional supplement containing critical nutrients including vitamin D, amino acids, bioavailable omega-3 and omega-6 fatty acids for cognitive health, and low glycemic sugar has the essential components needed to nourish the aging population.

GlycosBio’s line of products developed using its proprietary technology platform offers advantages over traditional formulas that are hard to digest and full of processed sugar.  For elderly with difficulty maintaining weight due to lack of interest in food or avoiding eating because of digestive sensitivities,  personalized highly bioavailable products offers a new choice for healthy independent living.   

  1. "WHO | Definition of an older or elderly person". Retrieved 2016-04-04.

  2. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Ali Sumbul and Jose M. Garcia, Gerontology. (2014); 60(4):294-305


HIV Associated Exocrine Pancreatic Insufficiency and Wasting Syndrome

One of the hallmark features of Acquired Immune Deficiency Syndrome (AIDS) due to HIV infection is involuntary weight loss also known as “wasting syndrome” or cachexia. Prior to 1996 before viral protease inhibitors were introduced, more than 60% of patients presented with protein energy malnutrition (PEM), leading to life-threatening opportunistic infections. 80% of HIV infected individuals succumbed to their disease due to cachexia (1).  With the advent of antiretroviral therapies, patients with HIV are living longer but still need support to manage the nutritional requirements for continued remission and the digestion issues caused by therapies. In one study of HIV infected people on antiretroviral therapy, over 50% suffered from EPI (2)

GlycosBio's highly bioavailable nutritional products are specifically formulated to support EPI and help prevent malnutrition in fragile and high need individuals where weight maintenance is a struggle, offering a new solution for high impact complete nutrition.

  1. Reversal of Cachexia in Patients Treated With Potent Antiretroviral Therapy. Scevola, D, et al., (2000) AIDS Read.10(6)

  2. Exocrine pancreatic insufficiency is common in people living with HIV on effective antiretroviral therapy. Aylin Yilmaz and Lars Hagberg Infectious Diseases (2018) volume 50, Issue 3


>> Read more about GlycosBio medical foods


Copyright © 2020 GlycosBio Food Sciences